Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market by Brand (Nesina, Tradjenta, Onglyza, Januvia, Others) and by Application (Type 2 Diabetes, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03280

Pages: NA

Charts: NA

Tables: NA

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. These inhibitors function by increasing incretin levels which in turn increases insulin secretion, thus decreasing blood glucose levels.

Increase in incidence of diabetes and its related complications such as cardiovascular disease, nephropathy, retinopathy, and neuropathy and rise in geriatric population fuel the market growth. However, side effects of the medicine such as urinary tract infection and respiratory tract infection restraints the market growth.

The global dipeptidyl peptidase-4 (DPP-4) inhibitors market is segmented based on brand, application, and region. Based on application, the market is divided into type 2 diabetes and others. On the basis of brand, the market is classified into Nesina, Tradjenta, Onglyza, Januvia, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market include Sanofi, Takeda Pharmaceuticals, Eli Lilly, Merck, Novo Nordisk, Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim.

Key Benefits

  • The study provides an in-depth analysis of the global dipeptidyl peptidase-4 (DPP-4) inhibitors market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides information about the current and upcoming trends in the global dipeptidyl peptidase-4 (DPP-4) inhibitors market which helps to determine the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key market players are profiled and their strategies are analyzed thoroughly, which help understand the competitive outlook of the market.

 Key Market Segments

  • By Brand
    • Nesina
    • Tradjenta
    • Onglyza
    • Januvia
    • Others
  • By Application
    • Type 2 Diabetes
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Bristol-Myers Squibb
  • Pfizer
  • Merck
  • Boehringer Ingelheim
  • Novo Nordisk
  • AstraZeneca
  • Eli Lilly
  • Sanofi
  • Takeda Pharmaceuticals
  • GlaxoSmithKline

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET, BY BRAND

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Brand

    • 4.2. Nesina

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Tradjenta

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Onglyza

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Januvia

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Type 2 Diabetes

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Others

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Brand

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.2.5.1. Market Size and Forecast, By Brand
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.2.6.1. Market Size and Forecast, By Brand
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.2.7.1. Market Size and Forecast, By Brand
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Brand

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.3.5.1. Market Size and Forecast, By Brand
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.3.6.1. Market Size and Forecast, By Brand
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.3.7.1. Market Size and Forecast, By Brand
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.3.8.1. Market Size and Forecast, By Brand
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.3.9.1. Market Size and Forecast, By Brand
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.3.10.1. Market Size and Forecast, By Brand
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.3.11.1. Market Size and Forecast, By Brand
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Brand

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.4.5.1. Market Size and Forecast, By Brand
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.4.6.1. Market Size and Forecast, By Brand
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.4.7.1. Market Size and Forecast, By Brand
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.4.8.1. Market Size and Forecast, By Brand
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.4.9.1. Market Size and Forecast, By Brand
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.4.10.1. Market Size and Forecast, By Brand
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.4.11.1. Market Size and Forecast, By Brand
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.4.12.1. Market Size and Forecast, By Brand
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.4.13.1. Market Size and Forecast, By Brand
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Brand

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.5.5.1. Market Size and Forecast, By Brand
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.5.6.1. Market Size and Forecast, By Brand
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.5.7.1. Market Size and Forecast, By Brand
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.5.8.1. Market Size and Forecast, By Brand
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.5.9.1. Market Size and Forecast, By Brand
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Dipeptidyl Peptidase-4 (dpp-4) Inhibitors Market

        • 6.5.10.1. Market Size and Forecast, By Brand
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Sanofi

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Takeda Pharmaceuticals

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Eli Lilly

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Merck

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Novo Nordisk

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Bristol-Myers Squibb

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Pfizer

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. AstraZeneca

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. GlaxoSmithKline

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Boehringer Ingelheim

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR NESINA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR TRADJENTA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR ONGLYZA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR JANUVIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR TYPE 2 DIABETES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 14. U.S. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 15. U.S. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 16. CANADA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 17. CANADA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 27. ITALY DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 28. ITALY DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 31. UK DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 32. UK DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 40. CHINA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 41. CHINA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. INDIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 45. INDIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 67. UAE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 68. UAE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY BRAND, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 73. SANOFI: KEY EXECUTIVES
  • TABLE 74. SANOFI: COMPANY SNAPSHOT
  • TABLE 75. SANOFI: OPERATING SEGMENTS
  • TABLE 76. SANOFI: PRODUCT PORTFOLIO
  • TABLE 77. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. TAKEDA PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 79. TAKEDA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 80. TAKEDA PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 81. TAKEDA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 82. TAKEDA PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. ELI LILLY: KEY EXECUTIVES
  • TABLE 84. ELI LILLY: COMPANY SNAPSHOT
  • TABLE 85. ELI LILLY: OPERATING SEGMENTS
  • TABLE 86. ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 87. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. MERCK: KEY EXECUTIVES
  • TABLE 89. MERCK: COMPANY SNAPSHOT
  • TABLE 90. MERCK: OPERATING SEGMENTS
  • TABLE 91. MERCK: PRODUCT PORTFOLIO
  • TABLE 92. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. NOVO NORDISK: KEY EXECUTIVES
  • TABLE 94. NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 95. NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 96. NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 97. NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. BRISTOL-MYERS SQUIBB: KEY EXECUTIVES
  • TABLE 99. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 100. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 101. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 102. BRISTOL-MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. PFIZER: KEY EXECUTIVES
  • TABLE 104. PFIZER: COMPANY SNAPSHOT
  • TABLE 105. PFIZER: OPERATING SEGMENTS
  • TABLE 106. PFIZER: PRODUCT PORTFOLIO
  • TABLE 107. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 109. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 110. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 111. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 112. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. GLAXOSMITHKLINE: KEY EXECUTIVES
  • TABLE 114. GLAXOSMITHKLINE: COMPANY SNAPSHOT
  • TABLE 115. GLAXOSMITHKLINE: OPERATING SEGMENTS
  • TABLE 116. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
  • TABLE 117. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 119. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 120. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 121. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 122. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET
  • FIGURE 3. SEGMENTATION DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET
  • FIGURE 11. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET SEGMENTATION, BY BY BRAND
  • FIGURE 12. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR NESINA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR TRADJENTA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR ONGLYZA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR JANUVIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 18. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR TYPE 2 DIABETES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS MARKET
  • FIGURE 26. TOP PLAYER POSITIONING, 2024
  • FIGURE 27. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. TAKEDA PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. TAKEDA PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. TAKEDA PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. ELI LILLY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. ELI LILLY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. ELI LILLY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. MERCK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. MERCK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. MERCK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. NOVO NORDISK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. NOVO NORDISK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. BRISTOL-MYERS SQUIBB: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. PFIZER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. PFIZER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. PFIZER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. ASTRAZENECA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. ASTRAZENECA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. GLAXOSMITHKLINE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. GLAXOSMITHKLINE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. GLAXOSMITHKLINE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. BOEHRINGER INGELHEIM: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved